Reply: A Road Less Traveled: To a Finite Chronic Hepatitis B Therapy Reply

Grishma Hirode; Harry L. A. Janssen

doi:10.1053/j.gastro.2022.05.012

Reply: A Road Less Traveled: To a Finite Chronic Hepatitis B Therapy Reply

Grishma Hirode^*
, Harry L. A. Janssen

^*Corresponding author for this work

Gastroenterology & Hepatology

The Toronto Viral Hepatitis Care Network (VIRCAN)
Toronto General Hospital

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

5 Downloads (Pure)

Original language	English
Pages (from-to)	779-780
Number of pages	2
Journal	Gastroenterology
Volume	163
Issue number	3
DOIs	https://doi.org/10.1053/j.gastro.2022.05.012
Publication status	Published - Sept 2022

Bibliographical note

Funding Information:
Conflicts of Interest This author discloses the following: Harry L.A. Janssen has received grants from AbbVie, Gilead Sciences, Janssen, and Roche and is a consultant for AbbVie, Bristol Myers Squibb, Gilead Sciences, Janssen, Merck, Roche, Arbutus, and Vir Biotechnology Inc. Grishma Hirode discloses no conflicts.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1053/j.gastro.2022.05.012

1-s2.0-S0016508522005017-mainFinal published version, 231 KBLicence: Article 25fa Dutch Copyright Act

Cite this

@article{d7f8d98bcd0945f8b5b38485b74b1e54,

title = "Reply: A Road Less Traveled: To a Finite Chronic Hepatitis B Therapy Reply",

author = "Grishma Hirode and Janssen, \{Harry L. A.\}",

note = "Funding Information: Conflicts of Interest This author discloses the following: Harry L.A. Janssen has received grants from AbbVie, Gilead Sciences, Janssen, and Roche and is a consultant for AbbVie, Bristol Myers Squibb, Gilead Sciences, Janssen, Merck, Roche, Arbutus, and Vir Biotechnology Inc. Grishma Hirode discloses no conflicts.",

year = "2022",

month = sep,

doi = "10.1053/j.gastro.2022.05.012",

language = "English",

volume = "163",

pages = "779--780",

journal = "Gastroenterology",

issn = "0016-5085",

publisher = "W.B. Saunders",

number = "3",

}

TY - JOUR

T1 - Reply: A Road Less Traveled

T2 - To a Finite Chronic Hepatitis B Therapy Reply

AU - Hirode, Grishma

AU - Janssen, Harry L. A.

N1 - Funding Information: Conflicts of Interest This author discloses the following: Harry L.A. Janssen has received grants from AbbVie, Gilead Sciences, Janssen, and Roche and is a consultant for AbbVie, Bristol Myers Squibb, Gilead Sciences, Janssen, Merck, Roche, Arbutus, and Vir Biotechnology Inc. Grishma Hirode discloses no conflicts.

PY - 2022/9

Y1 - 2022/9

UR - https://www.scopus.com/pages/publications/85135830987

U2 - 10.1053/j.gastro.2022.05.012

DO - 10.1053/j.gastro.2022.05.012

M3 - Comment/Letter to the editor

C2 - 35598630

SN - 0016-5085

VL - 163

SP - 779

EP - 780

JO - Gastroenterology

JF - Gastroenterology

IS - 3

ER -

Reply: A Road Less Traveled: To a Finite Chronic Hepatitis B Therapy Reply

Bibliographical note

UN SDGs

Access to Document

Other files and links

Cite this